Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Vitamin D has been shown to play an important immunomodulatory role; deficiency of vitamin D has been recently associated to the lack of response to antiviral therapy in chronic hepatitis C patients. This study evaluated the interrelationship between serum level of vitamin D and early response to antiviral therapy in Egyptian patients with chronic HCV infection. A total of 45 patients with chronic HCV infection who received antiviral treatment (Pegylated interferon and Ribavirin), their vitamin D serum level was assessed once at the start of treatment and 12 weeks later, when the EVR was determine by Quantitative HCV-RNA by PCR. The results showed that vitamin D status has no correlation with viral load and hepatitis activity by biopsy and without significant association between vitamin D deficiency and the antiviral therapy response. However, there was significance improvement in level of vitamin D after 12 weeks of receiving the antiviral therapy of HCV.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.12816/0010845 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!